Login / Signup

[Anogenital warts-An update].

David ChromySteffi SillingUlrike WielandAlexander Kreuter
Published in: Dermatologie (Heidelberg, Germany) (2023)
With a prevalence of around 1% in the sexually active population anogenital warts are the most frequent human papillomavirus (HPV)-related disease. In the vast majority of cases the underlying cause of the infection is due to HPV types 6 and 11. The diagnosis can usually be clinically established but in certain cases a histopathological work-up can be useful. Buschke-Lowenstein tumors represent such a scenario. The current therapeutic armamentarium for anogenital warts ranges from surgical ablative procedures up to local immunomodulatory treatment. All procedures have different advantages and disadvantages and are relatively time-consuming and sometimes also unpleasant for the patient. Anogenital warts are also a possible expression of an incomplete immunological control of HPV. Therefore, it should be emphasized that for certain affected individuals, especially immunosuppressed patients, special attention should be given to ensuring that screening investigations for HPV-associated dysplasia is carried out according to the respective valid guidelines. The primary prophylaxis by vaccination of girls and boys prior to first HPV exposure represents a very effective option to drastically reduce the prevalence of anogenital warts and other HPV-related diseases.
Keyphrases
  • high grade
  • cervical cancer screening
  • end stage renal disease
  • risk factors
  • chronic kidney disease
  • poor prognosis
  • ejection fraction
  • peritoneal dialysis
  • clinical practice
  • patient reported outcomes